Loading phase: Initial protocols often use 2-2.5mg twice weekly for 4-6 weeks
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
Significant reduction in melanin index is seen usually after 10 weeks
To ensure the proper safety of each patient, individuals interested & seeking IM therapy must first meet with a doctor, then undergo bloodwork evaluation
Injection burden 12 injections most days Best for Independent dose control Cycle driver Compound-specific phasing BPC-157 Loading 250500 mcg, daily Frequency Daily Maintenance 250 mcg, daily Route SubQ TB-500 Loading 2.05.0 mg, 2x/week Frequency 2x/week (loading), 12x/week (maintenance) Maintenance 2.0 mg, 12x/week Route SubQ Example Weekly Schedule (Loading Phase) Monday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Tuesday BPC-157 500 mcg SubQ Wednesday BPC-157 500 mcg SubQ Thursday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Friday BPC-157 500 mcg SubQ Saturday BPC-157 500 mcg SubQ Sunday BPC-157 500 mcg SubQ Use separate sterile syringes for separate-vial draws
Patients would require either two (2) devices (for a 56 mg dose) or three (3) devices (for an 84 mg dose) per treatment
.webp)
